



REMARKS

In order to be responsive to the Advisory Action of October 2, 2002, applicants have elected to delete peptide DM2* in claim 9.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Robert E. McCarthy, Reg. No. 46,044
Representative Capacity


Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 812-5322
Facsimile: (703) 243-6410

Filed: November 1, 2002

K:\Merck\2034\REPLY.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO THE CLAIM

9. (Amended) A modified recombinant allergen according to claim 8, selected from:

PM1 (N³² ⇒ D, D⁴⁹ ⇒ L, K⁵⁰ ⇒ A) (SEQ ID NO. 88)

PM2 (D⁴⁹ ⇒ L, K⁵⁰ ⇒ A) (SEQ ID NO. 89)

PM3 (A¹³ ⇒ C) (SEQ ID NO. 90)

DM1 (Δ K⁵⁰ ⇒ P^{Δ132}, D⁴⁹ ⇒ L) (SEQ ID NO. 91)

DM2 (Δ F⁵¹ - G¹⁷⁸, D⁴⁹ - L, K⁵⁰ - A) (SEQ ID NO. 92) or

~~DM2* (Δ F51 - G178, 179 - 217 altered sequence) or~~

DM3 (Δ A¹⁵⁴ - T¹⁷⁷, A²²⁰ ⇒ T) (SEQ ID NO. 93).